Reversal of HO-1 related cytoprotection with increased expression is due to reactive iron.
It is often postulated that the cytoprotective nature of heme oxygenase (HO-1) explains the inducible nature of this enzyme. However, the mechanisms by which protection occurs are not verified by systematic evaluation of the physiological effects of HO. To explain how induction of HO-1 results in protection against oxygen toxicity, hamster fibroblasts (HA-1) were stably transfected with a tetracycline response plasmid containing the full-length rat HO-1 cDNA construct to allow for regulation of gene expression by varying concentrations of doxycycline (Dox). Transfected cells were exposed to hyperoxia (95% O(2)/5% CO2) for 24 h and several markers of oxidative injury were measured. With varying concentrations of Dox, HO activity was regulated between 3- and 17-fold. Despite cytoprotection with low (less than fivefold) HO activity, high levels of HO-1 expression (greater than 15-fold) were associated with significant oxygen cytotoxicity. Levels of non-heme reactive iron correlated with cellular injury in hyperoxia whereas lower levels of heme were associated with cytoprotection. Cellular levels of cyclic GMP and bilirubin were not significantly altered by modification of HO activity, precluding a substantial role for activation of guanylate cyclase by carbon monoxide or for accumulation of bile pigments in the physiological consequences of HO-1 overexpression. Inhibition of HO activity or chelation of cellular iron prior to hyperoxic exposure decreased reactive iron levels in the samples and significantly reduced oxygen toxicity. We conclude that there is a beneficial threshold of HO-1 overexpression related to the accumulation of reactive iron released in the degradation of heme. Therefore, despite the ready induction of HO-1 in oxidant stress, accumulation of reactive iron formed makes it unlikely that exaggerated expression of HO-1 is a cytoprotective response.
Suttner
D M
DM
Department of Pediatrics, Stanford University School of Medicine, Stanford, California 94304, USA.
Dennery
P A
PA
D000818:Animals; D001663:Bilirubin / Q000032:analysis; D002248:Carbon Monoxide / Q000378:metabolism; D006224:Cricetinae; D004318:Doxycycline / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D005978:Glutathione / Q000032:analysis; D006157:Guanosine Monophosphate / Q000032:analysis; D006418:Heme / Q000378:metabolism*; D006419:Heme Oxygenase (Decyclizing) / Q000235:genetics / Q000378:metabolism*; D051547:Heme Oxygenase-1; D007501:Iron / Q000378:metabolism*; D018384:Oxidative Stress / Q000502:physiology; D010100:Oxygen / Q000633:toxicity*; D011994:Recombinant Proteins / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis
D011994:Recombinant Proteins; D017392:Thiobarbituric Acid Reactive Substances; D006418:Heme; D002248:Carbon Monoxide; D006157:Guanosine Monophosphate; D007501:Iron; D006419:Heme Oxygenase (Decyclizing); D051547:Heme Oxygenase-1; D005978:Glutathione; D004318:Doxycycline; D001663:Bilirubin; D010100:Oxygen